Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Fabi

Showing results (241-250 of 265) with videos related to

Pageof 27
Sort By:
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.
Cancers|October 14, 2023
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyStefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Frontiers in Oncology|April 24, 2025
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practiceStefania Gori, Alessandra Fabi, Catia Angiolini, et al.
NPJ Breast Cancer|February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
Cancer Treatment Reviews|August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical reviewAlberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.
Journal of Cellular Physiology|November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast CancerTeresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
NPJ Breast Cancer|May 6, 2021
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
Journal of Neurosurgical Sciences|April 30, 2020
Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) documentRoberta Rudà, Filippo F Angileri, Tamara Ius, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
Pageof 27

Showing results (241-250 of 265) with videos related to

Sort By:
Pageof 27
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.
Cancers|October 14, 2023
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyStefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Frontiers in Oncology|April 24, 2025
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practiceStefania Gori, Alessandra Fabi, Catia Angiolini, et al.
NPJ Breast Cancer|February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
Cancer Treatment Reviews|August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical reviewAlberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.
Journal of Cellular Physiology|November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast CancerTeresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
NPJ Breast Cancer|May 6, 2021
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
Journal of Neurosurgical Sciences|April 30, 2020
Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) documentRoberta Rudà, Filippo F Angileri, Tamara Ius, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
Pageof 27